Navigation Links
Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
Date:10/1/2010

ortantly, show their support for Kibow's progress in promoting healthy kidney function worldwide.

About Kibow Biotech:

Kibow Biotech, Inc. is a 13-year-old R&D biotechnology company, having its operations in Newtown Square, PA, USA. The company's mission is dedicated to finding a simple, convenient and cost-effective worldwide solution for people experiencing kidney function problems. The company's flagship product is called "Kibow(R) Biotics," an orally consumable, enteric-coated Gel Cap product formulation that is composed of food-grade microbes ("Probiotics") which metabolize the uremic toxins diffusing into the bowel as a consequence of increased levels of these toxins in the blood. The purpose of this non-drug, dietary supplement product is to help maintain a healthy kidney function for people in need of alternative or complementary Over The Counter (OTC) products.

Forward-looking statements:

Kibow(R) Biotics or any other dietary supplement is not intended to diagnose, treat, cure or prevent any disease as per the U.S. FDA. Kibow's website contains both historical information and also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are not guarantees of future performance. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks, uncertainties and other factors that may cause the actual results or performance of the Company to be materially different from such statements or from any future results or performance implied thereby. Factors which could cause the Company's results or performance to differ from current expectations include, but are not limited to, the ability to comply with regulatory requirements applicable to the manufacture and marketing of the Company's products; the Company's ability to obtain and enforce effective patents; the non-infringement of third party patents or proprietar
'/>"/>

SOURCE Kibow Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function
2. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
3. Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Yongye Biotechnology International Retains CCG Investor Relations
6. ThirdBiotech Announces Kemeta as Newest Sponsor
7. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
8. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
9. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
10. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
11. China Kangtai Cactus Biotech Announces Record Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , ... July 29, 2015 , ... ... PRC Clinical, a Silicon Valley-based CRO specializing in Clinical Trial Management. CSSi ... patient recruitment services. The core expertise of PRC Clinical is focused on Clinical ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... cell culture products, announces the availability of BI’s line of human mesenchymal stem ... these stem cell differentiation media offer a complete system for multipotency evaluation of ...
(Date:7/28/2015)... , July 29, 2015 ... acquiring, rapidly developing and commercialising innovative ... health   Highly experienced management team; blue ...   Mereo BioPharma Group Ltd ("Mereo"), ... raised $119m ( c. £76.5m), gross, from blue chip ...
(Date:7/28/2015)... Nev. , July 28, 2015  PDL BioPharma, ... today announced that the Company will release its second ... 30, 2015, on Wednesday, August 5, 2015, after market ... webcast that day at 4:30 p.m. Eastern Time to ... the call will be available via the webcast link ...
Breaking Biology Technology:CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 2CSSi LifeSciences And PRC Clinical Join Forces To Offer Extended Clinical Trial Services 3Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 2Rainbow Scientific, Inc. Announces Availability of Human Mesenchymal Stem Cell Differentiation Media 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... ONTY ) today reported financial results for the three ... product pipeline update. Management will hold a conference call today ... details). , Oncothyreon reported a loss from operations of $2.8 ... with a loss from operations of $3.6 million for the ...
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: ... and advances a diverse portfolio of promising cancer-related products ... financial results for the first quarter of fiscal 2010, ... quarter, we continued to advance our lead drug nimotuzumab, ...
... MADRID, November 11 Cellerix, a product-focused,biopharmaceutical company ... the successful first closing of its financing round,raising EUR27 ... a select group of new investors. Cellerix completed another,financing ... This round was led by the ...
Cached Biology Technology:Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 2Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 3Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 4Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 5Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 6Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 7Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 2YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 3YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 4YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 5YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 6YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 7YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 8YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 9YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 10YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 11YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS 12Cellerix Raises EUR27 Million in a First Closing 2
(Date:7/13/2015)... SAN JOSE, Calif. , July 13, 2015 ... the leading developer of human interface solutions, today ... second generation touch and display driver integration (TDDI) ... solution is the first to combine Synaptics , ... expertise with proven display driver technology developed in ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs ... announcing its acquisition of Avid Nano. Avid Nano ... scattering (DLS) systems.    Also today, ... fastest and easiest to use protein sizing system. ... measures a protein,s hydrodynamic size, size distribution, aggregation ...
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... of a small segment of DNA in the genome of ... of ancient animals from sea to land, or to later ... evidence" that copied DNA elements known as retroposons could be ... the research, Howard Hughes Medical Institute investigator David Haussler. ...
... the neighborhood bully so your buddy can get some tail ... works for some lizards, it also gives a fascinating peek ... their year on earth looking to reproduce, and their strategies ... edition of the Proceedings of the National Academy of Sciences ...
... along ?a siesta after a hearty lunch is natural, new ... for the first time uncovered how brain cells or 'neurons' ... , The findings ?published in the scientific journal Neuron this ... well as understanding levels of consciousness. , "It has been ...
Cached Biology News:Mobile DNA part of evolution's toolbox 2Mobile DNA part of evolution's toolbox 3Mobile DNA part of evolution's toolbox 4Nice guys do finish first in lizards' evolutionary race 2Why we could all do with a siesta 2
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Epi-Grids™ Colony Grid Templates are easy-to-use griding templates that allow rapid organization of colonies from initial screening plates and for preparing precise master plates....
Biology Products: